B.1.1.7, the Highly Infectious Coronavirus Variant, Could Soon Dominate the U.S. Prevention 2/9/2021 Korin Miller
A highly infectious coronavirus variant that was first detected in the U.K. is now rapidly spreading in the U.S. The variant, B.1.1.7, has been detected in at least 34 states so far and is expected to continue circulating.
A new preprint study estimates that cases of the variant are doubling in the U.S. every nine days, with an increased transmission rate of up to 45%.“Our study shows that the U.S. is on a similar trajectory as other countries where B.1.1.7 rapidly became the dominant SARS-CoV-2 variant, requiring immediate and decisive action,” the researchers wrote.
How Effective Is AstraZeneca’s COVID-19 Vaccine? Here’s What Experts Know so Far Prevention 2/14/2021
Replay Video UP NEXT
The COVID-19 vaccine developed by AstraZeneca and Oxford University has been approved for emergency use in Europe, Mexico, and India.
The vaccine has been proven to be effective against common strains of the novel coronavirus, but seems to offer little protection from the South African variant; the country has now stopped offering this vaccine to its citizens.
It’s unclear when the AstraZeneca vaccine could gain approval from the FDA.
A vaccine created by the University of Oxford and biopharmaceutical company AstraZeneca can protect people from developing a serious form of COVID-19 and slow the transmission of the virus, according to new research. While previous vaccines have shown they help reduce the risk of serious complications from the novel coronavirus, this is the first to suggest that it can actually reduce person-to-person spread.
Chest Pain? The Causes Could Go Beyond a Heart Problem, Doctors Say Prevention 1/23/2021 Stephanie Dolgoff
This article was medically reviewed by Raj Dasgupta, M.D., an associate professor of clinical medicine at the Keck School of Medicine of USC and member of the Prevention Medical Review Board, on January 21, 2021.
There it is: that discomfort in your chest. It’s probably from the pizza you just inhaled. But wait it
is chest pain. In the moment, it’s not a giant leap from
pass the Tums to
could it be my heart?
Well, yeah, it could, and you absolutely need to rule it out (more on that below). But the odds are also very good that it’s something else and not life-threatening.
What to Know About Johnson & Johnson’s Single-Dose COVID-19 Vaccine Prevention 3/12/2021 Korin Miller
Johnson & Johnson’s single-dose COVID-19 vaccine has been authorized for emergency use by the U.S. Food and Drug Administration.
On March 10, President Joe Biden announced his intent to purchase an additional 100 million doses of the
Johnson & Johnson vaccine.
The Johnson & Johnson vaccine was 85% effective at preventing severe or critical forms of COVID-19 28 days after vaccination and 100% effective at preventing COVID-related deaths in the company’s phase 3 clinical trial.
Johnson & Johnson’s COVID-19 vaccine began shipping out to states on March 1 after receiving authorization from the Food and Drug Administration (FDA) on February 27. Unlike its mRNA, two-dose vaccine competitors from Pfizer-BioNTech and Moderna, this one requires just a single dose.